Dr. Hyams is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
39000 Bob Hope Dr
Kiewit Building Suite 207
Rancho Mirage, CA 92270Phone+1 760-773-3311Fax+1 760-773-3811
Education & Training
George Washington UniversityResidency, Surgery, 1984 - 1986
National Cancer InstituteResidency, Nuclear Medicine, 1983 - 1984
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1981 - 1983
University of California (San Francisco)Residency, Surgery, 1978 - 1981
Columbia University Vagelos College of Physicians and SurgeonsClass of 1978
Certifications & Licensure
CA State Medical License 1980 - 2025
NY State Medical License 2010 - 2017
OH State Medical License 1988 - 2006
PA State Medical License 1994 - 2004
MD State Medical License 1982 - 1996- American Board of Surgery Surgery
Awards, Honors, & Recognition
- Palm Springs Life Magazine Castle Connolly, 2007-2014
- Top Doctors:LA Area Castle Connolly, 2013
- Top Doctors:San Diego Area Castle Connolly, 2013
- Join now to see all
Publications & Presentations
PubMed
- Neoadjuvant Cetuximab Leading to a Complete Pathologic Response in Locally Advanced Lip Squamous Cell Carcinoma.Ruba Alchaikh Hassan, Zahra Gafarzadeh, Shiva Salmasi, David M Hyams, Constantin A Dasanu
Cureus. 2024-12-01 - Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene exp...David M Hyams, Avital Bareket-Samish, Juan Enrique Bargallo Rocha, Sebastian Diaz-Botero, Sandra Franco
Journal of Surgical Oncology. 2024-08-01 - 2 citationsManagement of melanoma: can we use gene expression profiling to help guide treatment and surveillance?Jonathan S Zager, David M Hyams
Clinical & Experimental Metastasis. 2024-08-01
Press Mentions
Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDxDecember 4th, 2020
Castle Biosciences Presents Expanded Data Supporting Use of DecisionDx-Melanoma Test to Inform Sentinel Lymph Node Biopsy RecommendationsNovember 25th, 2019- Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual MeetingJune 4th, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
